Fish Oil for Inflammatory Bowel Disease: Panacea or Placebo?

Gastroenterol Clin North Am. 2021 Mar;50(1):169-182. doi: 10.1016/j.gtc.2020.10.010. Epub 2021 Jan 5.

Abstract

Dietary supplements have increasingly gained popularity over the years not only to replete micronutrient deficiencies but for their use in treatment of disease. The popularity of dietary supplements for inflammatory bowel diseases (IBD) arises from their perceived ease of use, potential disease-modifying benefits, and perceived safety. Overall, randomized controlled trials have not consistently shown a benefit of fish oil for the maintenance of remission with Crohn's disease. The inconsistency of these findings highlights the need for more studies that are powered to clarify the context in which omega-3 fatty acids might have a role in the treatment algorithm of IBD.

Keywords: Dietary supplements; Docosahexaenoic acid (DHA); Fish oil; Inflammatory bowel disease, eicosapentaenoic acid (EPA); Omega-3 fatty acids; α-Linolenic acid (ALA).

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • Fatty Acids, Omega-3* / therapeutic use
  • Fish Oils / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy

Substances

  • Fatty Acids, Omega-3
  • Fish Oils
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid